Harry J. Leonhardt
2017 - Halozyme Therapeutics
In 2017, Harry J. Leonhardt earned a total compensation of $1.8M as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at Halozyme Therapeutics, a 10% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $242,582 |
---|---|
Option Awards | $550,000 |
Salary | $425,000 |
Stock Awards | $550,006 |
Other | $11,070 |
Total | $1,778,658 |
Leonhardt received $550K in stock awards, accounting for 31% of the total pay in 2017.
Leonhardt also received $242.6K in non-equity incentive plan, $550K in option awards, $425K in salary and $11.1K in other compensation.
Rankings
In 2017, Harry J. Leonhardt's compensation ranked 6,091st out of 14,666 executives tracked by ExecPay. In other words, Leonhardt earned more than 58.5% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 6,091 | 59th |
Manufacturing | 2,240 | 61st |
Chemicals And Allied Products | 708 | 66th |
Drugs | 545 | 69th |
Biological Products, Except Diagnostic Substances | 100 | 68th |
Leonhardt's colleagues
We found four more compensation records of executives who worked with Harry J. Leonhardt at Halozyme Therapeutics in 2017.
News
Poseida Therapeutics CEO Mark Gergen's 2022 pay jumps 55% to $4.4M
April 26, 2023
Poseida Therapeutics CEO Eric Ostertag's 2021 pay jumps 633% to $6.3M
April 27, 2022
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019